BioCampus Investor Day - Review
Over 200 participants gathered in Basel to celebrate a pivotal moment for our region: the very first BioCampus Upper Rhine Investor Day.
Mini-symposium on the topic of quantum technology
In the form of a mini-symposium, representatives of a multidisciplinary audience of experts discussed the application of quantum technology in research, clinics and industry.
Innovation project with Pfizer Pharma GmbH
In an interactive, 1.5-day workshop format, the principles of design thinking were explained and effective methods for problem analysis, customer orientation and idea generation were taught.
CapCo Bio GmbH: Modular nanoplatform for targeted drug delivery
CapCo Bio GmbH is a deep-tech spin-off of the University Medical Centre Freiburg (Extracellular Vesicles working group). The company develops innovative nanotechnological solutions to transport therapeutic nucleic acids into cells in a targeted, safe and efficient manner.
CorTec GmbH: When technology meets neurons
CorTec GmbH develops neural interfaces that connect electronic systems directly to the nervous system. These technologies allow neural signals to be measured precisely and stimulated in a targeted manner.
PICO BioScience GmbH: Revolution in protein analysis
PICO BioScience GmbH is a Freiburg-based life science start-up that is setting new standards in protein analysis with its proprietary Protein Interaction Coupling (PICO) technology.
LABMaiTE GmbH: AI for the cell biology of the future
LABMaiTE uses artificial intelligence to analyse cell biological processes and supports research teams in evaluating complex experimental data more quickly and reproducibly.
Dermagnostix GmbH: Rethinking skin diagnostics
Dermagnostix develops molecular diagnostic systems for dermatology that enable fast, objective and reproducible results. The platforms combine microfluidic technology with molecular analysis and complement conventional histological procedures.
BioCopy AG: Accelerating drug development
BioCopy develops AI and automation-based platforms for accelerated drug development, particularly for biotherapeutics in oncology.
Averbis GmbH: Turning data into decisions
Averbis GmbH specialises in AI-supported analysis of unstructured health data. With the help of natural language processing (NLP) and machine learning, clinical texts, findings and documentation are converted into structured, interoperable information.